TargetMol

Lomeguatrib

Product Code:
 
TAR-T2495
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2495-5mg5mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2495-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2495-10mg10mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2495-25mg25mg£147.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2495-50mg50mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2495-100mg100mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2495-500mg500mg£667.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lomeguatrib, a modified guanine base, inhibits the activity of DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (MGMT) .
CAS:
192441-08-0
Formula:
C10H8BrN5OS
Molecular Weight:
326.17
Pathway:
Chromatin/Epigenetic; DNA Damage/DNA Repair
Purity:
0.9962
SMILES:
Nc1nc(OCc2cc(Br)cs2)c2nc[nH]c2n1
Target:
DNA Methyltransferase; DNA Alkylation

References

1. McElhinney RS, et al. J Med Chem, 1998, 41(26), 5265-5271. 2. Clemons M, et al. Br J Cancer, 2005, 93(10), 1152-1156. 3. Middleton MR, et al. Int J Cancer, 2000, 85(2), 248-252.